



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 12, 2022

Steven Burden, Ph.D.  
Chief Executive Officer  
Facible BioDiagnostics, Inc.  
366 SW 5th Ave, Ste. 104  
Meridian, ID 83642

**Re: Facible BioDiagnostics, Inc.**  
**Offering Statement on Form 1-A**  
**Filed May 9, 2022**  
**File No. 024-11878**

Dear Dr. Burden:

This is to advise you that we do not intend to review your offering statement.

We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report.

Please contact Jane Park at 202-551-7439 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Nicholas Antaki, Esq.